Latest News - Merck KGaA
Top Corporates Hub
Merck KGaA
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield
23.12.2025 08:45
Discover why Bristol-Myers Squibb's growth surge and strong dividends make BMY a compelling investment.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More
18.12.2025 13:50
Pre-Market Stock Futures: Futures are trading higher on Thursday as we grind closer to the Christmas holiday, which is just a week off now. The song remains the same for the AI/Datacenter trade, and participants are finding it’s going to be a bit tougher here at the end of the year than in the last ... Here Are Thursday’s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More
Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says
15.12.2025 16:14
Merck (MRK) is expected to deliver mid-single-digit revenue growth in fiscal 2026 driven primarily b
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
15.12.2025 14:32
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
LGND: 2025 Analyst Day
15.12.2025 11:04
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its 2025 analyst day on December 9 th , 2025, at the Harvard Club in New York City. The morning presentations highlighted the company’s achievements for 2025 and looked ahead to 2026, providing financial guidance for the next year. Details of the event are included in a press
Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026
12.12.2025 17:43
They could grow into their valuation over the next few years.
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
12.12.2025 15:35
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Does WINREVAIR’s CHMP-Backed Label Expansion Shift The Bull Case For Merck (MRK)?
12.12.2025 15:11
In early December 2025, Merck reported that the EMA’s Committee for Medicinal Products for Human Use recommended expanding WINREVAIR’s EU indication to cover adults with pulmonary arterial hypertension in WHO Functional Class II, III and IV, based on Phase 3 ZENITH data in high‑risk patients. This positive opinion, following recent U.S. label updates, strengthens WINREVAIR’s profile as a first‑in‑class activin signaling inhibitor and could broaden its clinical and commercial reach in severe...
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
12.12.2025 15:03
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
12.12.2025 13:45
RAHWAY, N.J., December 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV based on the Phase 3 ZENITH study. The cu
2 Mega-Cap Stocks with Exciting Potential and 1 We Ignore
12.12.2025 04:32
Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavily to expand further, a risky proposition.
Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1
11.12.2025 12:33
Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $104 to $122 and maintained a Buy rating on the stock. A day earlier, on December 4, the company announced receiving […]
Why Analysts Think Merck Could Be Undervalued As Its Pipeline Story Evolves
11.12.2025 01:06
Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its pipeline. With revenue growth expectations trimmed only marginally and the discount rate left effectively unchanged at around 6.96%, the shift reflects nuanced optimism rather than a wholesale rerating. Stay tuned to see how you can keep track of these incremental adjustments as the story around...
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
09.12.2025 13:00
TORONTO, December 09, 2025--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada.
How Protein And Pets Drove Elanco Animal Health's 79% Gain In 2025
09.12.2025 12:40
Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
09.12.2025 11:51
There's hope for U.S. cattle ranchers in the battle to stop the spread of screwworm at a time of decimated herds with the FDA approving a new Merck treatment.
Strategic Pharma Collaborations Propel RCC Market Growth
09.12.2025 10:27
The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi
These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now
09.12.2025 00:30
Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
07.12.2025 13:43
With yields between 3.4% and 6.8%, you'll need to think carefully about the highest yields in the Dow before you buy them.